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Abstract.  mAbs raised against the human nuclear ma- 
trix (anti-NM) 1 mAbs have been used to investigate 
the role of nuclear matrix antigens in pre-mRNA pro- 
cessing.  The three anti-NM mAbs used in this study 
recognize antigens that are highly localized to nuclear 
matrix  speckles.  Surprisingly,  all three of these mAbs 
preferentially immunoprecipitate  splicing complexes 
containing  exon sequences. The anti-NM mAbs 
efficiently immunoprecipitate the exon product com- 
plex but not complexes containing the lariat product 
after the second step of splicing.  Two of the anti-NM 
mAbs completely inhibit pre-mRNA splicing in vitro. 
However, none of the.anti-NM mAbs appear to recog- 
nize factors stably associated with splicing snRNPs. 
The three anti-NM mAbs predominantly react with 
distinct high molecular weight antigens,  which belong 
to a class of nuclear proteins that selectively precipi- 
tate with Ser-Arg protein-splicing factors in the pres- 
ence of high Mg  2+ concentrations.  Immunological, bio- 
chemical,  and cell biological data indicate that two of 
the NM antigens are related to the defined set of Ser- 
Arg proteins.  The results suggest the existence of an 
extended Ser-Arg family as a component of the nu- 
clear matrix. 
S 
INCE the discovery of pre-mRNA splicing in 1977, con- 
siderable progress has been made towards elucidating 
the mechanism underlying this process. A spliceosome 
containing  multiple  small  nuclear ribonucleoprotein parti- 
cles (snRNPs)~ and non-snRNP protein factors executes the 
precise cleavage and ligation steps generating mature mRNA 
(reviewed in Guthrie,  1991; Moore et al.,  1993). However, 
much less is known about the factors which specify splice 
site selection in pre-mRNA and the nature of the changes in 
this process involved in the recognition  and regulation of al- 
ternative  spliced pre-mRNAs. Furthermore, it is not known 
whether the pre-mRNA splicing process is co-ordinated with 
other processes of gene expression,  in particular,  transcrip- 
tion and RNA transport.  Insight  into these questions may 
emerge from the determination  of precise relative locations 
in the nucleus  of structures involved in RNA processing. 
Factors  involved  in the transcription  and processing of 
precursor RNA are highly  localized  to distinct subnuclear 
structures.  The  largest  and  best studied of these are the 
nucleoli in which ribosomal precursor RNA is transcribed, 
processed  and  packaged  into  ribosome  subunits.  Recent 
studies  using  fluorescent-tagged  antibody and nucleic  acid 
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probes show that pre-mRNA splicing factors are enriched in 
at least two distinct  types of nuclear  structure.  The most 
prevalent  of these correspond to "speckles" of which there 
are typically 20-50 present in  a mammalian  cell nucleus 
(reviewed  in  Spector,  1993).  There  are  also one  to  five 
"coiled bodies" detected in the majority of mammalian nuclei 
(reviewed in Lamond and Fonseca,  1993).  Both structures 
are sites of enrichment  of U2, U4/6,  and U5 snRNPs and 
also non-snRNP splicing factors.  U1 snRNP is also present 
in  these  structures  although  it is  also widely distributed 
throughout  the nucleus.  Also, speckles,  but not coiled bod- 
ies,  are sites  of polyA+RNA accumulation,  as detected by 
hybridization  in  situ  with  oligo-dT  (Carter  et  al.,  1991, 
1993). 
The immunofluorescent  speckled staining  pattern corre- 
sponds  to  the  interchromatin  granule  clusters  and  peri- 
chromatin fibril network seen in conventional embedded EM 
sections (Spector et al.,  1991). Resinless EM sections have 
shown that the speckled immunofluorescence  pattern corre- 
sponds  to dense assemblies located within  the matrix  fila- 
ment network (Nickerson et al.,  1992; Wan et al.,  1994). 
While the precise relationship  of these nuclear structures to 
RNA processing is not clear,  newly synthesized  RNA, de- 
tected by labeling with a short pulse of [3H]uridine, primar- 
ily localizes to the perichromatin fibril region and not the in- 
terchromatin  granules (Fakan et al., 1976). Most introns are 
spliced while the nascent RNA is still in the process of elon- 
gation  and  therefore  proximal  to the gene (Beyer and Os- 
heim,  1988). Based on these observations,  it has been pro- 
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the perichromatin fibril region whereas posttranscriptional 
splicing, as well as splicing factor storage, assembly, and/or 
recycling may occur in interchromatin granules. 
Recent studies, using high-resolution immunofluorescent 
microscopy of in situ hybridization probes,  have revealed 
that certain  viral  and cellular pre-mRNA  transcripts  are 
localized within the confines of curvilinear "tracks" (Law- 
rence et al.,  1989;  Huang and Spector,  1991; Xing et al., 
1993).  These tracks emerge from the corresponding gene 
and generally extend out towards the nuclear periphery. In 
instances where tracks are observed, the corresponding gene 
is co-incident with or located near to one of the nuclear 
speckles (Huang and Spector, 1991; Xing et al., 1993). The 
RNA track emerging from this focus usually contains intron 
sequences  only  in  the  gene-proximal  part  of the  track, 
whereas exon sequences are detected throughout the track, 
thus it is possible that certain pre-mRNA transcripts  are 
processed during nuclear export along a vectorial pathway. 
The nucleus is highly organized, with factors sorted to dis- 
crete domains, usually according to their particular func- 
tional association. In addition to speckles and coiled bodies, 
other localized structures include those implicated in tran- 
scription (Jackson et al., 1993; Wansink et al., 1993; Xie et 
al., 1993) DNA replication (Nakamura et al., 1986;  Naka- 
yasu and Berezney, 1989; Hoz,'ik et al., 1993), as well as do- 
mains of unknown function (Ascoli and Maul, 1991; Saun- 
ders et al., 1991; Stuurman et al., 1992). The organizational 
principles of subdomains in the nucleus are not well under- 
stood. Most of these domains remain associated with a sub- 
nuclear structure after the majority of chromatin and soluble 
nuclear material has been removed. This "nuclear matrix" 
has been generated under a variety of different experimental 
conditions (reviewed in Nickerson and Penman, 1992). The 
nuclear matrix retains over 70% of nuclear RNA, including 
the majority of hnRNA (Herman et al., 1978; Miller at al., 
1978; van Eekelen et al., 1981; He et al., 1990). The earliest 
pulse-labeled RNA transcripts that can be detected are as- 
sociated with the matrix (Jackson and Cook,  1985).  Un- 
spliced and spliced mRNAs of specific genes have also been 
detected in the matrix suggesting that pre-mRNA processing 
occurs on this structure (Mariman et al., 1982; Schr'6der et 
al., 1987a,b).  Direct support for this was provided by Zeitlin 
et al. (1987, 1989) who showed that a ~-globin pre-mRNA 
associated with isolated matrix is rapidly processed follow- 
ing the addition of a soluble nuclear fraction. Furthermore, 
it has been shown that components in speckles,  and also 
RNA tracks, remain quantitatively associated with the nu- 
clear matrix (NM) following nuclear extraction (Vogelstein 
and Hunt, 1982;  Spector et al., 1983; Xing and Lawrence, 
1991). 
The identification of specific roles for matrix factors will 
be important for understanding the role of nuclear substruc- 
ture in the organization, and potentially the regulation, of 
pre-mRNA processing.  Several mAbs that were raised against 
nuclear matrix preparations identify a class of integral nu- 
clear matrix proteins which preferentially associate with a 
specific subset of pre-mRNA splicing complexes. These an- 
tigens are non-snRNP splicing factors, two of which may be- 
long to the Ser-Arg  family of proteins. This study suggests 
a fundamental role for specific nuclear matrix proteins in the 
nuclear organization of pre-mRNA processing. 
Materials and Methods 
Microscopy 
CaSki cells (a human cervical carcinoma cell line: CRL 1550;  American 
Type Culture Collection, Rockville, MD) were grown on glass coverslips. 
Cells were washed with PBS at 4°C and then extracted at 4°C in CSK Buffer 
(10 mM Pipes, pH 6.8, 100 mM NaC1,  300 mM sucrose, 3 mM MgC12, 
1 mM EGTA)  containing 0.5 %  (wt/vol) Triton X-100,  20 mM vanadyl 
riboside complex, and  1 mM 4-(2-aminoethyl) benzenesulfonyl fluoride 
(AEBSF). For immunofluorescent staining of cells with the H1B2 mAb, 
chromatin was first removed by digestion for 50 rain at 32"C with 400 U/ml 
DNaseI in digestion buffer (10 mM Pipes, pH 6.8, 300 mM sucrose, 50 mM 
NaC1,  3  mM  MgC12,  1  mM  EGTA)  containing 0.5%  (wt/vol)  Triton 
X-100, 20 mM vanadyl riboside complex, and 1 mM AEBSE followed by 
extraction in 0.25 M ammonium sulfate as described previously (Nickerson 
et al., 1992).  This step was included to expose the H1B2 antigen which is 
partially masked by chromatin. Cells were fixed with 4% paraformaldehyde 
in CSK buffer for 20--40 min at 4°C. After fixation, cells were washed with 
PBS and blocked in 10%  normal goat serum (NGS) in PBS for 30 min at 
32°C. Antibody incubations were performed in PBS containing 2% NGS 
or in tissue culture supernatant (for anti-SC35 mAb) for 1 h at 32°C. After 
three to four washes in PBS, samples were incubated with fluorochrome- 
coupled second antibodies in PBS containing 2 % NGS. For double-label 
experiments using two mAbs, the second Abs were Ig class-specific goat 
anti-mouse IgG coupled to fluorescein, goat anti-mouse IgM coupled to 
rhodamine, or anti-mouse IgM coupled to Texas Red. Following extensive 
washing in  PBS,  coverslips were mounted using VectaShield mounting 
medium (Vector Laboratories, Burlingame, CA). 
In the immunostaining-competition experiment (see Fig. 10), each anti- 
NM mAb was titrated to determine the minimum concentration required 
for clear immunofluorescent detection, mAbs at these dilutions were pre- 
incubated with or (for control samples) without 40 #g/ml of  purified SR pro- 
teins in PBS containing 2 % NGS. The pre-incubated mAbs were then used 
for immunofluorescent staining of cells as described above. 
For resinless section electron microscopy and  immunogold labeling, 
CaSki cells were extracted to uncover core filaments of the nuclear matrix 
as previously described (He et al., 1990).  Immunogold labeling of the ma- 
trix preparation using the IMA11 mAb and a colloidal gold-conjugated sec- 
ond antibody was performed as described by Nickerson et al.  (1992). 
HeLa Cell Nuclear Splicing Extracts and 
SR Protein Purification 
HeLa nuclear extracts were prepared essentially as described by Dignam 
et al. (1983).  Depletion of SR proteins from HeLa nuclear extracts was per- 
formed during nuclear extract preparation, before the final dialysis step 
against buffer I3.  Nuclear extract in buffer C  was aliquoted into 0.5-ml 
amounts in microdialysis vessels (Sartorius Balances, Westbury, NY) and 
dialyzed against 3  ×  1 liter changes of dialysis buffer (DB buffer: 65 raM 
KC1, 15 mM NaC1,  10 mM Hepes, pH 7.6, 1 mM Na2EDTA,  2 mM DTT, 
5 mM KF, 5 mM/~-glycerophosphate, 0.2 mM PMSF; Zahler et al., 1992) 
in a beaker surrounded by a jacket of ice. Dialyzed extracts were microfuged 
for 5 min at 4°C to pellet non-specific precipitate and the cleared superna- 
tants transferred to new tubes. The dialyzed extract was incubated on ice 
for 1 h with MgC12, added from a 1 M stock solution, to a final concentra- 
tion of 20 mM. One half of  the nuclear extract was microfuged twice at 4°C 
(1  x  30 min, then in a new tube, 1 x  15 min) to pellet SR proteins (=Spin 
+  NE). The other half was left on ice (=Spin  -  NE). The Spin +  and 
Spin -  extracts were dialyzed against 3 x  1 liter changes of buffer D (Dig- 
ham et al.,  1983),  aliquoted into 0.1 ml amounts, and then snap frozen in 
liquid nitrogen. The Spin +  NE pellet fraction was washed twice in DB 
buffer containing 20 mM MgCl2, solubilized in buffer D (Dignam et al., 
1983)  containing 5% glycerol, and then snap frozen in liquid nitrogen. 
SR proteins used in splicing assays were purified from HeLa cells essen- 
tially as described by Zahler et al.  (1992). 
In Vitro Splicing Assays 
Splicing assays containing regular HeLa cell nuclear extracts were per- 
formed using in vitro transcribed, capped and uniformly 32p-labeled pre- 
mRNA substrates, essentially as previously described (Grabowski et al., 
1984).  Splicing assays using Spin +  NE and Spin -  NE were performed 
without additional MgCh added, but otherwise under identical conditions 
as for assays using regular HeLa  nuclear extract. RNA recovered from 
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mRNA (Moore and Sharp,  1992) was analyzed on 15% polyacrylamide 
(1:30, bisacrylamide/acrylamide)/8 M urea denaturing gels run in 1 × TBE 
buffer. Splicing/immunoprecipitation assays with the/3-globin pre-mRNA 
(AL4; Lamond et al.,  1987) were analyzed on 8% polyacrylamide  (1:30, 
bisacrylamide/acrylamide)/8 M urea denaturing gels. 
Immunoprecipitations 
Immunoprecipitation of splicing  complexes  was  carried out in "IPIO0" 
buffer (100 mM NaC1, 2 mM MgC12, 0.5 mM DTT, 0.05% NP-40, 50 rnM 
Tris/HC1, pH 7.6). Protein A beads (Pharmacia Fine Chemicals, Piscata- 
way, NJ) (pre-swollen  overnight in IP100  containing 0.05 % azide)  were 
washed twice in fresh IP100 before use. Beads were pre-coated  with 10 ~g 
rabbit anti-mouse Ig's (Pierce Chemical Co., Rockford,  IL) for 1 h in 150 
~1 IPI00, then washed three times in IP100 before coupling monoclonals. 
Beads were incubated with the monoclonals for 2-3 h, washed three times, 
and then resuspended in 300 tzl IP100. Splicing reactions (typically  60 t~l 
containing 30% nuclear extract, vol/vol) were incubated with the Ab beads 
for 1.5 h. Beads were washed three times (quick washes) in IP100 and im- 
munoprecipitated RNA eluted by incubation for 40 win at 65"C in 300 td 
proteinase K buffer (0.5% SDS,  100 mM NaC1, 10 mM Trs-HC1, pH 7.6) 
containing 15 ~  proteinase K (20 mg/ml) and 1.5 td glycogen (20 mg/ml). 
30 #1 of protein A beads (packed bead volume) was used per immunoprecip- 
itation. Protein A beads were centrifuged at all times at 3-4K in a bench-top 
microfuge,  and all incubation steps were carried out at 4°C, unless stated 
otherwise. 
Immunoprecipitation  of snRNPs from HeLa nuclear extracts was carried 
out exactly as described previously (Blencowe et al.,  1993). 
Northern Analysis 
Immunoprecipitated RNA was separated on 10% polyacrylamide (1:30 bis 
acrylamide/acrylamide)/8  M  urea denaturing gels run in 1 ×  TBE buffer. 
Electrophoresed RNA was electroblotted and then UV cross-linked onto 
Hybond "N" nylon membrane (Amersham Corp., Arlington Heights,  IL). 
Detection of snRNAs was carried out using snRNA-specific riboprobes as 
described by Biencowe et al. (1989). 
SDS-PAGE and Western Blot Analysis 
For Western blots probed with the B1C8 and B4All mAbs, proteins sepa- 
rated in SDS-polyacrylamide gels were transferred to nitrocellulose mem- 
brane using a semi-dry ¢lectrotransfer apparatus (Bio-Rad  Laboratories, 
Cambridge, MA).  For blots probed with the HIB2 mAb, proteins were 
transferred onto nitrocellulose  by wet transfer for 6 h, and then incubated 
under conditions to denature then renature proteins, as described previously 
(Vinson et al., 1988). All blots were pre-blocked in 3 % nonfat milk powder 
in PBS and then incubated with primary mAbs overnight at 4°C. Detection 
using a 2nd antibody conjugated to alkaline phosphatase was carried out as 
previously described (Harlow  and Lane,  1988). 
Results 
Nuclear Matrix Antigens B1C8, HIB2, and B4A11 
Co-localize with the Non-snRNP Splicing Factor SC35 
Murine mAbs raised against isolated NM preparations (anti- 
NM) from human cells were used to visualize intranuclear 
staining patterns in CaSki cells (a human cervical carcinoma 
cell line). Three anti-NM mAbs were selected which gave 
prominent punctate immunofluorescent staining patterns in 
interphase nuclei. Two of the anti-NM mAbs used in the 
present study, H1B2 and B1C8, have previously been shown 
to recognize antigens concentrated in nuclear matrix-asso- 
ciated structures which appear as speckles in immunofluo- 
rescence (Nickerson et al.,  1992;  Wan et al.,  1994).  The 
B4All mAb has also been shown to recognize an antigen re- 
tained in nuclear matrix preparations in a distinct speckled 
staining pattern (Fig.  1, see below). 
In the previous studies, the B1C8, H1B2, and B4A11 anti- 
gens were also shown to have strikingly different localization 
patterns during mitosis (Nickerson et al., 1992; Wan et al., 
1994;  J. A. Nickerson and S.  Penman, unpublished data). 
Both the H1B2 and B1C8 mAbs stain distinct regions of the 
mitotic spindle apparatus whereas the B4All antigen appar- 
ently becomes soluble during mitosis and cannot be detected 
in detergent-extracted cells. The very different behavior of 
these antigens during mitosis indicates that these three anti- 
NM mAbs recognize different proteins,  even though they 
have similar nuclear distributions during interphase. It is in- 
teresting to note that the dynamic redistribution of  the B4A11 
matrix antigen is similar to that observed for antigens recog- 
nized by the mAb SC35, which also are not detected from 
prophase to late telophase (Spector et at., 1991). In total nu- 
clear extracts this mAb reacts predominantly with SC35 as 
well as with other members of the Ser-Arg  (SR)  family of 
protein splicing factors (Fu and Maniatis, 1990;  Fu et al., 
1992).  As will be expanded upon below,  the SR family of 
proteins contain an NH2-terminal RNA recognition motif 
(RRM) and a COOH-terminal domain that is rich in Serine- 
Arginine diamino acid repeats (Zahler et al.,  1992).  It has 
been previously shown that the SC35 mAb stains interphase 
nuclei in a speckled pattern (Fu and Maniatis, 1990). 
In the present study, all three of the anti-NM mAbs were 
tested for recognition of sites of antigen concentration that 
are co-incident with nuclear speckles enriched in pre-mRNA 
splicing factors. Cells were stained with each of the anti-NM 
mAbs and then co-stained with a patient serum specific for 
Sm antigens of snRNPs. The anti-Sm serum gave a typical 
widespread intranuclear staining with sites of highest con- 
centration  in  speckled  structures,  whereas  the  anti-NM 
mAbs displayed much more restricted punctate staining pat- 
terns, co-localizing with Sm antigens predominantly in the 
speckled structures (data not shown). This suggests that all 
three anti-NM mAbs recognize antigens that are located in 
the subnuclear structure in which RNA splicing occurs. 
A direct comparison of the relative subnuclear locations 
of the anti-NM antigens and splicing factors was made using 
the SC35 mAb. Pairwise comparisons of the staining pat- 
terns obtained with the anti-NM mAbs, and with the SC35 
mAb, are  shown in Fig.  1.  This comparison used fluoro- 
chrome conjugated 2nd antibodies that are specific for differ- 
ent mAb isotypes (B1C8 and H1B2 are IgM's whereas B4All 
and SC35  mAbs are IgG's).  Confocal images of ceils co- 
stained with the different anti-NM mAbs are shown in red 
and green in the second and third columns. Combinations of 
mAbs used are indicated to the right of the figure. Superim- 
position of the red and green images is shown in the fourth 
column.  Precise colocalization of the anti-NM and SC35 
mAb staining, represented by areas of  yellow coloration, was 
detected in  the  speckled  structures.  This comparison re- 
vealed a  similar but nonidentical staining pattern for the 
different anti-NM mAbs. For example, every speckled do- 
main stained by the H1B2 mAb was also stained by B4A11, 
although B4All  also  stained several  additional sites  that 
were not stained by H1B2 (note the additional sites labeled 
by B4AI 1 in green in the overlay with H1B2). By contrast 
the  BtC8  and  SC35  mAbs,  while  displaying  extensive 
colocalization  with  each  other,  both  stained  additional, 
nonoverlapping, speckled domains detected as the separate 
red and green speckles in the overlay. 
The structures underlying speckles are integral to the nu- 
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removal of  chromatin. Resinless section electron microscopy 
of chromatin depleted nuclei shows the nuclear matrix to be 
comprised of a dense, highly interconnected network of illa- 
ments (termed core filaments) bounded by the nuclear lam- 
ina.  The  filament  network,  seen  in  Fig.  1 B,  enmeshes 
numerous dense structures. These structures have been dec- 
orated by immunogold labeling with the B4A11  mAb and 
therefore must correspond to the speckles observed in im- 
munofluorescence.  Previous  studies  have  shown  that  the 
H1B2 and B1C8 mAbs give similar results (Nickerson et al., 
1992; Wan et al.,  1994). 
The data in Fig.  1 show that antigens recognized by the 
anti-NM rnAbs B1C8, H1B2, and B4A11 are highly localized 
to nuclear speckles in which the pre-mRNA splicing factor 
SC35 is also concentrated. While the antigens recognized by 
these antibodies extensively co-localize with each other, the 
overlap does not extend to every nuclear speckle. This indi- 
cates that individual nuclear speckled domains may differ 
from each other in their specific protein composition. The 
different staining patterns observed further supports the no- 
tion that the anti-NM mAbs recognize distinct nuclear ma- 
trix antigens. To address whether the anti-NM mAbs recog- 
nize antigens that are involved in RNA processing, each was 
assayed for interactions with pre-mRNA splicing complexes 
assembled in vitro. 
Association of  Antigens of the Nuclear Matrix with 
Pre-mRNA Splicing Complexes 
Fig. 2 shows the results of using each anti-NM mAb to im- 
munoprecipitate splicing complexes assembled in vitro on 
different radiolabeled pre-mRNA substrates. An efficiently 
spliced pre-mRNA substrate, PIP85A, was first incubated in 
splicing  reactions to generate splicing complexes. Immu- 
noprecipitations were then carried out from these reactions 
using beads pre-coupled to each of the different anti-NM 
mAbs  (Fig. 2 A,  lanes  7-9).  A  mAb (Y12;  Lerner et al., 
1981) specific for the common (Sm) snRNP-associated anti- 
gens was assayed in parallel as a positive control for splicing 
complex immunoprecipitation (Fig. 2 A, lane 6). RNA re- 
covered  following  immunoprecipitation  was  separated 
alongside a sample of RNA extracted directly from a parallel 
splicing reaction (Fig. 2 A, lane 3). In the absence of mAb, 
or in the presence of a nonspecific control mAb, little or no 
immunoprecipitation of RNA was observed (Fig. 2 A, lanes 
4 and 5). By contrast, the anti-Sm mAb resulted in efficient 
immunoprecipitation of unspliced pre-mRNA and both the 
intermediates and products of the splicing reaction (Fig. 2 
A, lane 6). Strikingly, all three of the anti-NM mAbs also 
efficiently immunoprecipitated different RNA species from 
the splicing reaction. However, there was a significant differ- 
ence in the ratios of splicing intermediates to products im- 
munoprecipitated by anti-NM mAbs compared to anti-Sm 
mAb. The anti-NM mAbs consistently immunoprecipitated 
more of the splicing intermediates relative to lariat product 
than did the anti-Sm mAb. This was particularly striking in 
the case of the B1C8 and B4All m_Abs. A quantitative com- 
parison of immunoprecipitation levels in Fig. 2 A showed the 
ratio of 3' exon-lariat intermediate to lariat product to be 2.9- 
fold higher for B1C8 mAb than for anti-Sm mAb and, in the 
case of B4All,  this ratio was 2.5-fold higher (Fig.  2 D). 
H1B2 also preferentially immunoprecipitated the lariat inter- 
mediate versus lariat product compared to Sm, although the 
difference in the ratios of these reaction species is less pro- 
nounced (1.6-fold higher; Fig. 2 D) than for the B1C8 and 
B4A11 mAbs,  (Fig. 2 A, compare lane 9 with lane 6). 
The data in Fig. 2 A show that the different anti-NM mAbs 
recognize antigens that are preferentially associated with un- 
spliced pre-mRNA and the RNA intermediates of the in vitro 
splicing  reaction.  To  determine  the  specificity  of these 
antigen-RNA interactions in more detail, the ability of each 
anti-NM  mAb  to  immunoprecipitate two  RNAs  of com- 
pletely different sequence was tested (Fig. 2 B). Immunopre- 
cipitations were'carried out using the same mAbs as in Fig. 
2  A,  but from splicing  reactions incubated with  either a 
~-globin pre-mRNA  substrate  (T3  RNA;  Lamond et al., 
1987) or a control RNA complementary to the/3-globin pre- 
mRNA (T7 RNA).  Splicing reactions were incubated with 
equivalent amounts of the two different RNAs before immu- 
noprecipitation.  In  reactions  incubated  with  the /~-globin 
pre-mRNA, the three anti-NM mAbs all show a pattern of 
immunoprecipitation similar to that of the PIP85A substrate. 
As noted previously for all three mAbs,  a  higher ratio of 
splicing intermediates to lariat product was immunoprecipi- 
tated compared to the ratio obtained with the anti-Sm Y12 
mAb (Fig. 2 B, compare lanes 8-10 with lane 5). However, 
the ratios of lariat 3' exon intermediate/lariat product immu- 
noprecipitated by the anti-NM mAbs were typically higher 
(approximately threefold) for the ~-globin pre-mRNA sub- 
strate than for the PIP85A pre-mRNA (compare Fig.  2 B 
with  A;  see  Fig.  2  D).  The  three  anti-NM  mAbs  also 
efficiently immunoprecipitated the unspliced/3-globin pre- 
mRNA.  In  marked contrast  to  results  obtained  with  the 
PIP85A  and 13-globin pre-mRNA  substrates,  none of the 
anti-NM mAbs significantly immunoprecipitated the/3-glo- 
bin-complementary RNA above background levels (com- 
pare Fig. 2 B, lanes 12-14 with lane 11 ). In separate experi- 
ments,  a  similar pattern of immunoprecipitation was also 
observed  for  a  third  pre-mRNA  substrate  derived  from 
Figure 1. Immunolocalization of nuclear matrix antigens B1C8, H1B2, and B4A11. (A) B1C8, H1B2, and IMA11 colocalize with each other 
and with the non-snRNP splicing factor SC35. CaSki interphase nuclei are shown double labeled with combinations of  the different anti-NM 
mAbs and with anti-SC35 mAb, as indicated on the right of the figure. The red and green panels show the localization pattern of each 
individual mAb. Colocalization, which appears as a yellow coloration in the superimposed images, is shown in the fourth column. A phase 
contrast image of  each cell nucleus is shown in the first column. (B) High-resolution immunolocalization of  the IMA11 antigen in the nuclear 
matrix. CaSki cells were extracted to expose core filaments of the nuclear matrix which consist of a network of highly branched ,x,10-nm 
filaments connected to the nuclear lamina (L) (see low-magnification insert). The core filaments of the matrix suspend numerous dense 
structures which correspond to speckles detected by immunofluorescent staining. A subset of these structures are specifically decorated 
by the B4All mAb (see high-magnification micrograph, orientated sideways  with respect to the insert). The sites of  B4A11 antigen localiza- 
tion were detected in the micrograph using a colloidal gold-conjugated second antibody. Bar, 0.2 ttm. 
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noprecipitate exon-containing complexes from  in  vitro  splicing 
reactions. (,4) Pre-mRNA splicing reactions were incubated with a 
32P-labeled PIP85A RNA substrate for 45 min before immunopre- 
cipitation. RNA recovered following immunoprecipitation is shown 
in lanes 4-9. RNA recovered directly from a parallel splicing reac- 
tion is shown in lane 3 (represents 50% of the total RNA recovered; 
RNA from each immunoprecipitation  represents all of the RNA re- 
covered). Antibodies used are monoclonal anti-Sm (Y12) (lane 6), 
B1C8 (lane 7), 1MAll (lane 8), and HIB2 (lane 9). Non-specific 
control immunoprecipitations are with beads alone (lane 4) and 
with a monoclonal specific for the nuclear mititotic apparatus pro- 
tein (NuMA) (lane 5). Markers are unspliced PIP85A RNA (lane 
2) and end-labeled phiX174-Haem fragments (lane 1 ). (B) Immu- 
noprecipitation  of/3-globin pre-mRNA splicing complexes. Globin 
sense (T3) and antisense (/7) RNAs were incubated in splicing re- 
actions for 40 min before immunoprecipitation. Antibodies used 
for immunoprecipitation  are as in A. Two different nonspecific con- 
trol mAbs (to NuMA protein) are shown in lanes 7 and 11.  RNA 
recovered directly from the T3 and T7 RNA splicing reactions is 
shown  in lanes 1  and  2,  respectively; the amounts  shown  cor- 
respond to 50% of  the total sample whereas each immunoprecipita- 
tion lane represents the total RNA recovered. Markers are end- 
labeled pBR322-Mspl  fragments (lane 3).  (C)  Anti-NM mAbs 
(BIC8,  HIB2,  and  B4AI1)  preferentially immunoprecipitate the 
ligated exon product after the second step of pre-mRNA splicing. 
Immunoprecipitations were carded out as in A, but from splicing reactions that had been incubated for 2 h. Lanes 1-7 correspond directly 
to lanes 3-9 in Fig. 3 A. Markers (lanes 8 and 9) are as in Fig. 3 A.  (D) Quantitation of RNA immunoprecipitation levels. Shaded bars 
represent (in relative units) the ratio of exon-containing RNA to intron-lariat RNA immunoprecipitated by anti-Sm and anti-NM rnAbs. 
All values have been normalized to the corresponding exon RNA/intron RNA ratio in the total splicing reaction (=1). Relative ratios of 
/3-globin lariat 3' exon/lariat product immunoprecipitated from a 40' splicing reaction are shown in black. Ratios are also shown for the 
PIP85A lariat 3' exon/lariat  product immunoprecipitated from a 45' reaction (light grey bars) and PIP85A exon product/lariat  product immu- 
noprecipitated from a 2-h reaction (dark grey bars). The data were collected from the immunoprecipitation experirnents in A-C, which 
are representative of levels observed in several repeat experiments. We n0te.however that in many experiments, the ratios observed for 
the PIP85A pre-mRNA were higher than those shown here. The amount of each splicing reaction RNA species was determined using a 
Molecular Dynamics Phosporlmager. 
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shown). These data show that the anti-NM mAbs specifically 
and  stably bind to antigens that are  associated with pre- 
mRNA splicing substrates of different sequence.  Further- 
more,  an RNA molecule that does not contain functional 
splice sites, or assemble into pre-mRNA splicing complexes, 
is not immunoprecipitated by the anti-NM mAbs. 
The above data address interactions between antigens rec- 
ognized by anti-NM mAbs and splicing complexes that are 
assembled during the first 40-45 min of a splicing reaction 
in vitro. Previous analyses of the time course of splicing in 
vitro have shown that formation of spliceosomes is maxi- 
mum at about 40 rain. With further incubation, spliceosomes 
are largely resolved into complexes containing the reaction 
products. After the second step of splicing, the lariat product 
remains in a  stable  complex containing splicing  snRNPs 
(Konarska and Sharp,  1987).  By contrast, specific factors 
that remain associated with the exon product RNA of the 
splicing reaction have not been identified. 
The association of the NM antigens with the splicing reac- 
tion products was tested by immunoprecipitation after a 2-h 
incubation. Fig. 2 C shows immunoprecipitations from 2-h 
splicing reactions containing the PIP85A pre-mRNA, using 
the same mAbs as in Fig. 2 A. In the total reaction ~50% 
of the unspliced pre-mRNA has been converted to reaction 
products (Fig. 2 C, lane 1 ). The Y12 mAb preferentially im- 
munoprecipitated the lariat product relative to exon-product 
RNA (Fig. 2 C, lane 4). This is consistent with the known 
association of snRNPs with a lariat-product complex.  In- 
terestingly, the anti-NM mAbs show the opposite relative 
affinity for the products of the splicing reaction. All three 
mAbs preferentially immunoprecipitated the exon-product 
RNA compared to lariat product species (Fig. 2 C, compare 
lanes 5-7 with lane 4; see Fig. 2 D). As expected, a higher 
level of the splicing intermediates relative to lariat product 
was also immunoprecipitated by the anti-NM mAbs as com- 
pared to the Y12 mAb.  These data suggest that the B1C8, 
H1B2 and B4All  antigens are preferentially associated in 
vitro with splicing complexes that contain exon sequences. 
Furthermore, the ability of these mAbs to efficiently immu- 
noprecipitate the exon-product RNA shows that these anti- 
gens remain assembled on exons following the second step 
of the splicing reaction. 
Inhibition of  Splicing by Anti-NM mAbs 
The NM antigens recognized by the three mAbs could be es- 
sential pre-mRNA  splicing  factors.  The potential role  of 
these proteins in splicing was tested by incubating each anti- 
NM mAb in splicing reactions containing the PIP85A pre- 
mRNA (Fig. 3).  Interestingly, both the B1C8 (Fig. 3, lanes 
7-9) and B4All  (lanes 13-15) mAbs completely inhibited 
pre-mRNA splicing, whereas the H1B2 mAb (lanes 10-12) 
gave little or no inhibition, even when present at higher con- 
centrations than the other two mAbs. Two different control 
mAbs, 3C1 (lanes 16-18) and anti-actin (lanes 19-21 ), both 
of which are IgM's, gave little or no inhibition of pre-mRNA 
splicing. 3C1 is a mAb that labels a nuclear matrix antigen 
with a diffuse distribution (J. A. Nickerson and S. Penman, 
unpublished observations). In parallel experiments, addition 
of inhibitory concentrations of B4A11 and B1C8 mAbs at the 
beginning of a splicing reaction, prevented subsequent im- 
munoprecipitation  of the  unspliced  pre-mRNA  by  these 
Figure 3. Effect  of anti-nuclear matrix antibodies (BIC8, H1B2, and 
B4A11)  on  pre-mRNA splicing.  Splicing reactions containing 
PIPg5A RNA were incubated for 1 h in the presence of purified 
mAbs (lanes 4-21).  Three different amounts of each mAb were 
used, as indicated. Negative  controls for splicing inhibition include 
two IgM mAbs: 3C1 (lanes 16-18) and anti-actin (19-21). Anti-Sm 
(Y12) mAb was included  as a positive control for splicing inhibition 
(lanes 4-6). Lane 3 shows  splicing in the absence of mAb. Concen- 
trations of mAbs are: Y12, H1B2, 3C1, and anti-actin ,,ol mg/ml; 
BIC8 =  0.85 mg/ml, B4All  =  0.71 mg/ml. Markers are as in 
Fig. 2. 
mAbs (data not shown). By contrast, the H1B2 mAb, when 
incubated in splicing reactions at similar concentrations, still 
allowed  efficient  immunoprecipitation  of  splicing  com- 
plexes.  This suggests that the H1B2 mAb, but not the B1C8 
and B4All mAbs, binds stably to an antigen without pre- 
venting its assembly into splicing complexes, or interfering 
with the splicing reaction. 
Immunoprecipitation experiments were performed to de- 
termine if the NM-antigens are stable components of snRNPs 
involved in splicing.  Fig. 4  shows a  Northern analysis of 
spliceosomal snRNAs immunoprecipitated from a HeLa nu- 
clear extract by the different mAbs.  While mAbs against 
shared snRNP-associated structures (m3G cap and Sm anti- 
gens),  efficiently immunoprecipitate all four spliceosomal 
snRNPs (U1, U2, U4/6, and U5), the anti-NM mAbs did not 
significantly immunoprecipitate any  spliceosomal  snRNP 
species (compare lanes 3 and 4 with lanes 5-7).  In related 
experiments, total immunoprecipitates prepared from HeLa 
cell nuclear extracts using anti-m3G and anti-Sm Abs did not 
contain proteins  that could be detected on  western blots 
probed with the anti-NM m_Abs (data not shown). We con- 
clude that antigens recognized by the B1C8, B4A11 and H1B2 
mAbs are not stable components of spliceosomal snRNPs. 
Iramunoreactivity of  Anti-NM mAbs with SR Protein 
Splicing Factors 
The B1C8, B4All, and H1B2 mAbs recognize antigens that 
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splicing snRNPs.  RNA immunoprecipitated  from HeLa cell nu- 
clear extract with the anti-NM mAbs was probed on northern blots 
using 32p-labeled riboprobes specific for each of the spliceosomal 
snRNAs. RNA immunoprecipitated by the BIC8, H1B2, and IMAll 
rrLAbs is shown in lanes 5, 6 and  7, respectively. Anti-Sm (Y12) 
(lane 3) and anti-trimethylguanosine  (c~m3G) cap (lane 4) mAbs 
were used as positive controls  for snRNP  immunoprecipitation. 
Level of nonspeeific immunoprecipitation by a control mAb (anti- 
NuMA) is shown in lane 2. A sample of total HeLa RNA is shown 
in lane 1. Approximately 0.25 mg nuclear extract was used in each 
immunoprecipitation. 
could correspond to splicing factors that assemble separately 
of snRNPs into spliceosomes. In this regard, it is interesting 
to note that the pattern of subnuclear localization of  these an- 
tigens on the nuclear matrix resembles closely that observed 
for antigens recognized by the SC35 mAb (see Fig. 1). In ad- 
dition to having a similar nuclear distribution,  it was found 
that the SC35  mAb resulted in a  near identical pattern of 
splicing complex immunoprecipitation compared to the anti- 
NM mAbs (see Fig. 7 below). The SC35 mAb preferentially 
immunoprecipitated  exon-containing  RNA  intermediates 
and products from a splicing reaction. It is therefore possible 
that the anti-NM mAbs also recognize members of the SR 
protein family. 
Immunoblot analysis  has  shown  that  B1C8  mAb reacts 
principally with a  180-kD nuclear matrix protein and H1B2 
with a nuclear matrix protein of at least 240 kD (Nickerson 
et al.,  1992;  Wan et al.,  1994).  More recently, the B4All 
mAb was also found to react with a high molecular weight 
(•300  kD) nuclear matrix antigen (J. A. Nickerson and S. 
Penman, unpublished observations). Consistent with these 
observations, proteins of the same high molecular weights 
are also detected by the anti-NM mAbs in HeLa cell nuclear 
extracts (Fig. 5). In addition to these antigens however, B1C8 
shows strong reactivity with another protein, which typically 
appears as a diffuse band of 160 kD, and B4All shows minor 
reactivity with two proteins of around 80 kD (Fig. 5). Upon 
longer development of  the immunoblots, it was found that the 
B1C8  and  H1B2  mAbs  also  detect  additional  proteins  in 
HeLa  nuclear  extract,  including  those  with  molecular 
weights typical of the abundant SR proteins. 
Many SR proteins share a common phosphoepitope recog- 
nized by mAb 104. Six of the mAb 104 SR proteins (SRp's: 
Figure 5.  Detection of SR proteins by anti-NM  mAbs.  (.4) HeLa 
nuclear extract proteins were separated in a 12.5 % SDS gel, trans- 
ferred to nitrocellulose,  and probed  with mAb 104 (lane 1) and 
B1C8 (lane 3). A sample of purified SR proteins probed with mAb 
104 is shown as a marker in lane 2. (B and C) Purifed SR proteins 
transferred to nitrocellulose were probed separately with B1C8 (B, 
lane 1 ), H1B2 (C, lane 1 ), and mAb 104 (B and C, lanes 2). A sam- 
ple of purified SR proteins stained with coomassie is shown in C, 
lane 3.  (D-F) Proteins from Mg2+-treated HeLa nuclear extracts 
were separated in 10% SDS gels, transferred to nitrocellulose, and 
probed with the anti-NM mAbs. A nuclear extract treated with high 
Mg  2+ but not centrifuged is shown in lanes 1. A centrifuged Mg  2+ 
nuclear extract is shown in lanes 2. The pellet fraction of the cen- 
trifuged Mg  2÷ nuclear extract is shown in lanes 3.  D was probed 
with BIC8, E with B4A11, and F with H1B2. 
75, 55, 40, 30a, 30b, and 20 kD) can be rapidly purified to 
homogeneity by two precipitation steps, one of which uses 
a high concentration of Mg  2+ (Zahler et al.,  1992).  Besides 
these six SR proteins, mAb 104 also reacts with several addi- 
tional proteins in nuclear extract (see Fig.  8; Zahler et al., 
1993). These other mAb 104-reactive proteins are separated 
from the six SR proteins at an early step in the purification 
procedure.  Significantly  however,  they  are also efficiently 
precipitated by high Mg  2÷ concentrations and may therefore 
be related to SR proteins (Fig.  8; see below). It was of in- 
terest to note that one of the additional mAb 104 antigens 
is a 180-kD protein which comigrates with the B1C8 antigen 
(Fig. 5 A, compare lanes 1 and 3). To address whether the 
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proteins, all three anti-NM mAbs were used to separately 
probe preparations of purified SR proteins and also precipi- 
tates of nuclear extracts prepared with high Mg  2+. 
Both the B1C8 and HIB2 mAbs reacted with individual 
members of  the SR family. The B1C8 mAb selectively recog- 
nized the 30-kD SR protein species (Fig. 5 B, lane 1) and 
the H1B2 mAb detected the 55-kD SR protein (Fig. 5 C, lane 
I ). The 30-kD SR species consists of at least two different 
proteins of similar size, SC35 and the related splicing factor 
SF2/ASF (Zahler et ai., 1992). The B4AI1 mAb showed no 
immunoreactivity with any of the purified SR proteins (data 
not shown). In contrast to the reactivifies with the large pro- 
teins in nuclear extracts, B1C8 and H1B2 reacted relatively 
weakly with the purified SR proteins. 
The  high molecular weight proteins  recognized by the 
three matrix mAbs have epitopes in common with SR pro- 
teins and might share the common property of precipitation 
by Mg  2÷.  The presence of these antigens were assayed in 
preparations of HeLa nuclear extract incubated under condi- 
tions which resulted in efficient Mg  2÷ precipitation of SR 
proteins (see Materials and Methods for details). The levels 
of SR proteins in the depleted nuclear extract were assayed 
by Western blotting with mAb 104 (see Fig. 8). Significantly, 
all of the high molecular weight antigens recognized by the 
B1C8, B4A11, and H1B2 mAbs were also efficiently  depleted 
from the centrifuged Mg  2+ treated nuclear extract (SP  + 
NE, Fig. 5, D-F, lanes 2). The levels of most proteins in the 
treated nuclear extract, as detected by protein staining and 
probing with control mAbs, were not reduced by precipita- 
tion  with  Mg  2+,  and  none  of the  antigens were  depleted 
from extracts prepared without Mg  2+ incubation (data not 
shown). Futhermore, the antigens were not destroyed by the 
high Mg  2+ conditions as the levels of both mAb  104  and 
anti-NM mAb-reactive proteins were not altered in a treated 
extract that had not been centrifuged (SP -  NE, Fig. 5, D-E 
lanes 1; see also Fig. 8).  All of the major reactive antigens 
precipitated  by  Mg  2÷  were  recovered  intact in  the pellet 
fraction following centifugation (SP  +  Pel,  Fig.  5,  D-F, 
lanes 3), demonstrating that depletion in the centrifuged nu- 
clear extract was due to precipitation and not nonspecific 
losses. 
These results demonstrate that the high molecular weight 
antigens recognized by the three anti-NM mAbs belong to 
a class of nuclear proteins which are selectively precipitated 
by Mg  2+. This class of proteins include all of the mAb 104 
antigens (see Fig. 8), and may therefore extend to other pro- 
teins which contain an SR domain. Consistent with a rela- 
tionship between the high molecular weight NM antigens 
and SR proteins, the B1C8 and H1B2 mAbs also recognized 
at a  much lower efficiency individual members of the SR 
family. These two mAbs may therefore detect shared epi- 
topes on different subsets of related SR proteins. The mul- 
tiplicity of antigens detected by the anti-NM mAbs however 
complicates the interpretation of the role of the antigens that 
are: (a) specifically localized in nuclear matrix speckles; (b) 
functioning in splicing as indicated by antibody inhibition; 
and (c) associated with splicing complexes as indicated by 
preferential immunoprecipitation. It is possible that the anti- 
NM mAbs specifically interact with one or more SR-related 
proteins as antigens in all of these roles in splicing. To ad- 
dress this, different biochemical assays were used to inves- 
Figure 6. SR proteins restore splicing activity to anti-NM mAb- 
inhibited nuclear extracts. Splicing reactions were incubated with 
minimal inhibitory concentrations  of  different mAbs, together with 
increasing  concentrations  of  purified SR proteins, mAbs used (indi- 
cated at top of panel) are: anti-Sin (YI2) (lanes 4-7), B1C8 (lanes 
8-11, and 16-18), and B4AI1 (lanes 12-15). A control splicing 
reaction, without added antibody, is shown in lane 3. Purified SR 
proteins (1.6 mg/ml) were added to antibody-inhibited  reactions in 
a range from 0-6 #1, as indicated, v-globulin, (2 mg/ml) was added 
to a BICS-inhibited  extract as a negative  control for splicing recov- 
ery (lanes 16-18). 
tigate the role of epitopes shared with SR proteins in the rec- 
ognition of splicing complexes by the anti-NM mAbs. 
Restoration of Splicing Activity in BIC8 
mAb-inhibited Nuclear Extracts by the Addition of 
Purified SR Proteins 
Anti-Sm (Y12),  B1C8, or B4All  mAbs were added to the 
minimum level necessary to suppress splicing activity in nu- 
clear extract. Increasing concentrations of purified SR pro- 
teins were also added to these mAb-inhibited reactions (Fig. 
6).  This  addition restored  splicing  activity to  the  B1C8- 
inhibited reaction (Fig. 6, lanes 8-11) and, to a significantly 
lesser extent, the B4A11 inhibited reaction (lanes I2-15). By 
contrast, adding purified SR proteins to the Y12-inhibited 
reaction did not result in any detectable restoration of splic- 
ing activity. Furthermore, addition of equivalent levels of a 
control protein (-/-globulin)  to a B1CS-inhibited reaction did 
not result in any increase in activity. In a repeat experiment 
using instead a/~-globin pre-mRNA substrate, a very similar 
pattern of splicing activity was observed, indicating that the 
effects were not dependent on the particular sequence of the 
pre-mRNA  substrate  used  (data  not shown).  Addition of 
purified SR proteins to splicing reactions in the absence of 
inhibitory antibody resulted only in  a  minor  increase  in 
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purified SR proteins can specifically compete inhibition of 
splicing by the B1C8 mAb. The low level of splicing restora- 
tion in the B4All inhibited extract could be due to the low 
level of splicing stimulation upon addition of SR proteins. 
This would be consistent with the observation that B4A11 did 
not show detectable reactivity with one of the defined SR 
proteins. 
Preferential Immunoprecipitation of  Exon-containing 
Splicing Complexes by the Anti-SC35 mAb 
Inhibition of splicing by B1C8 and possibly B4All, may be 
due to the binding of these mAbs to one or more SR proteins 
in nuclear extracts. It was therefore of interest to determine 
whether  the  specific pattern  of immunoprecipitation  ob- 
tained with the anti-NM mAbs (Fig. 2) was due to the mAbs 
binding to SR proteins in splicing complexes. If this was cor- 
rect, then the SC35 mAb (Fu and Maniatis, 1990) might dis- 
play the same pattern of immunoprecipitation as the anti- 
NM  mAbs.  To test this,  immunoprecipitation of splicing 
complexes was carried out with the SC35 mAb in parallel 
with the anti-NM mAbs; Fig. 7 shows a comparison with the 
B4A11 mAb. The SC35 mAb shows an essentially identical 
pattern of immunoprecipitation as the B4A11 mAb, display- 
ing a distinct preference for splicing intermediates over the 
lariat-product species in a splicing reaction that has been in- 
cubated for 40 rain (compare lanes 5-7).  A quantitatively 
similar  immunoprecipitation  pattern  was  also  observed 
when both antibodies were also used to inununoprecipitate 
from splicing reactions that had been pre-incubated for 2 h. 
Immunoprecipitation with the SC35 mAb also specifically 
enriched for the exon-product RNA,  but not for the lariat 
product of the splicing reaction (data not shown). These data 
suggest that the preferential immunoprecipitation of exon- 
containing pre-mRNA splicing complexes by the anti-NM 
mAbs and anti-SC35 mAb may be due to the specific recog- 
nition of SR or related proteins by these mAbs. 
Reconstitution of  Pre-mRNA lmmunoprecipitation in 
SR-depleted Nuclear Extracts 
Immunoprecipitation of pre-mRNA from HeLa cell nuclear 
extracts by the anti-NM mAbs specifically requires SR pro- 
teins.  A  reconstitution experiment was performed (Fig.  8) 
using the SR depleted nuclear extract described in Fig. 5 (see 
Materials and Methods for details). Similar to the high mo- 
lecular weight antigens detected by the anti-NM mAbs, im- 
munoblot analysis using mAbl04 (Fig. 8 A) showed that pro- 
teins corresponding to the purified SR proteins (lane 6) were 
efficiently depleted from the centrifuged Mg  2÷ nuclear ex- 
tract (spin + NE, lane 3). The levels of these proteins were 
also not changed in a treated extract that had not been cen- 
trifuged (spin -  NE; compare lanes 2 and 4) and could be 
recovered intact in the pellet fraction following centrifuga- 
tion of the Spin  +  NE (lane 5). 
Analysis of splicing activity in the Spin +  and Spin -  ex- 
tracts showed that the Spin -  NE was active for processing 
of exogenous pre-mRNA, whereas the Spin +  NE was inac- 
tive, even in the presence of added SR proteins (Fig.  8 B; 
data not shown). The same preparation of SR proteins could 
however  restore  activity  to  an  S100  cytoplasmic  extract 
which is deficient in these proteins (Zahler et al., 1992; data 
not shown). This indicates that the Spin +  NE lacks one or 
Figure  7.  Immunoprecipita- 
tion  of  pre-mRNA  splicing 
complexes  with  anti-SC35 
mAb.  Immunoprecipitations 
were carried out as in Fig 3. 
mAbs  used  are:  anti-NuMA 
(lane 3), anti-Sin (YI2) (lane 
5), B4All (lane 6), and anti- 
SC35 (lane 7). Total splicing 
(lane 3) and markers (lanes 1 
and 2) are as in Fig 3 A. 
more essential splicing factors, in addition to the purified SR 
proteins. This hypothesis was confirmed by adding back the 
Mg  2÷ pellet fraction to the Spin  +  NE;  the reconstituted 
reaction yielded splicing levels comparable to those found in 
the Spin  -  NE (data not shown). 
To address whether the immunoprecipitation of splicing 
complexes by  the  anti-NM  mAbs  was  dependent  on  SR 
proteins,  a  reconstitution experiment was performed. The 
efficiency of specific immunoprecipitation of a pre-mRNA 
substrate  (PIP85A)  was  compared between the  anti-NM, 
SC35, 104, and Y12 mAbs from reactions containing either 
the Spin -  NE (lanes 1-7), Spin +  NE (lanes 8-14) or Spin 
+ ,NE to which purified SR proteins had been added (lanes 
!5r-21 ) (Fig. 8 B). Significantly, the levels of pre-mRNA im- 
munoprecipitated by all three of the anti-NM mAbs and the 
SC35 and 104 mAbs, was greatly reduced in the Spin +  NE 
(lanes 10-14) as compared to levels in the Spin -  NE (lanes 
3-7).  The decrease in pre-mRNA immunoprecipitation in 
the Spin  +  NE by these mAbs was not due to nonspecific 
losses,  since the nonimmunoprecipitated RNA was recov- 
ered intact in the supernatant fractions (Fig.  8 C). In con- 
trast to the anti-NM and mAbs to the SR proteins, the Y12 
mAb immunoprecipitated a similar level of pre-mRNA from 
the Spin  +  and Spin  -  extracts (compare lanes 2 and 9). 
Immunoprecipitation of pre-mRNA by the B1C8 and H1B2 
mAbs was fully restored by adding purified SR proteins to 
the Spin  +  NE extract (lanes 17 and 18). Similar results 
were observed for both the SC35 and 104 mAbs (lanes 20 
and 21). Addition of SR proteins to the Spin +  NE did not 
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depleted nuclear extracts. SR proteins were depleted from HeLa 
cell nuclear extracts by high-speed centrifugation in the presence 
of 20 mM Mg. (A) Levels of SR proteins in different nuclear ex- 
tracts assayed by Western blotting using mAb  104 (lanes 1-4). 
Lanes 3 and 4 show depleted and mock-depleted extracts respec- 
tively. Lane 5 shows the pellet fraction from the depleted extract 
in lane 3. Lane 2 shows a control, untreated nuclear extract. Lane 
6 shows purified SR proteins (sizes indicated on panel right). Lane 
1 shows pre-stained markers (sizes indicated on panel left). Ap- 
proximately 150 ~g of each nuclear extract was loaded in lanes 2, 
4, 5, and 6/zg purified SR proteins was loaded in lane 6. (B and 
C) Immunoprecipitations with different mAbs  were carded out 
from splicing reactions containing the nuclear extracts shown in A: 
RNA recovered from the pellet (B) and corresponding supernatant 
fractions (C) are shown. Each antibody was used to immunoprecip- 
itate from a splicing reaction containing either the mock-depleted 
"spin -  NE" (lanes 1-7), depleted "spin + NE" (lanes 8-14) or the 
"spin +  NE" to which SR proteins had been added (lanes 15-21 ). 
mAbs used are: Ctd mAb (anti-NuMA) (lanes 1, 8, and 15), anti- 
Sm (Y12) (lanes 2, 9, and 16), BIC8 (lanes 3, 10, and 17), H1B2 
(lanes 4, 11, and 18), B4All (lanes 5, 12, and 19), anti-SC35 (lanes 
6, 13, and 20) and mAb 104 (lanes 7, 14, and 21 ). The ratio of su- 
pernatant:pellet fraction loaded is 1:4; exposure times for (B) and 
(C) are approximately the same. 
however result in an increase in the level of pre-mRNA im- 
munoprecipitation by the Y12 mAb  (lane 16),  nor was a 
significant increase observed for the B4All mAb (lane 19). 
This indicates that the ability of the purified SR proteins to 
promote immunoprecipitation by the B1C8 and H1B2 mAbs 
in the Spin  +  NE was a  specific effect. These results, to- 
gether with the immunoblotting data in Fig. 5, provide the 
strongest argument for suggesting that the antigens recog- 
nized by B1C8 and H1B2 anti-NM mAbs are related to one 
or more SR proteins. By contrast, immunoprecipitation by 
the B4A11 mAb was not restored by addition of the purified 
SR proteins to the Spin +  NE.  This is consistent with the 
data  in  Fig.  5,  which  demonstrate  that  the  B4All  mAb 
recognizes an antigen that is depleted from the Spin +  NE 
but is not a constituent of one of the purified SR proteins. 
Competition of Speckled lmmunostaining by 
SR Proteins 
The immunofluorescence  data presented in Fig. 1 shows that 
the B1C8, H1B2, and B4A11 antigens are localized to nuclear 
matrix speckles which arc enriched in pre-mRNA splicing 
factors.  We performed another competition experiment to 
address whether this specific staining pattern on the nuclear 
matrix involves the recognition of determinants on SR pro- 
teins (Fig. 9). Each anti-NM mAb, and also the anti-SC35 
and Y12 mAbs, were pre-incubated with SR proteins prior 
to immunostaining. This effectively  blocked nuclear staining 
by the B1C8, H1B2,  and SC35 mAbs,  whereas the B4All 
mAb was only weakly competed and the Y12 mAb was not 
competed at all. In the presence of an equivalent concentra- 
tion of  a nonspeeific control protein, no competition of stain- 
ing by the B1C8, HIB2 and SC35 mAbs was observed (data 
not shown).  These data are consistent with the notion that 
both the B1C8 and H1B2 mAbs specifically recognize one or 
more SR-related antigens concentrated in the speckled pat- 
tern of the nuclear matrix. Moreover, the lack of significant 
competition  by SR proteins of  B4A11 mAb staining is further 
consistent with this mAb recognizing an epitope that is not 
present on one of the defined SR proteins. 
Discussion 
Pre-mRNA  splicing factors are concentrated in dense nu- 
clear matrix structures which correspond to speckled do- 
mains observed by immunofluorescence. In this report, the 
function of antigens concentrated in these structures was in- 
vestigated using three different murine mAbs raised against 
the human nuclear matrix (anti-NM mAbs) B1C8, H1B2, and 
B4A11. The experiments suggest that antigens recognized by 
these three mAbs participate in pre-mRNA  splicing.  The 
data are summarized in Table I. 
A striking feature of the mAbs is that they all preferentially 
immunoprecipitate splicing complexes that contain exon se- 
quences. Complexes containing unspliced pre-mRNA, RNA 
intermediates of splicing, and the ligated exon product RNA 
were all efficiently immunoprecipitated from in vitro splic- 
ing reactions by the anti-NM mAbs. By contrast, the anti- 
NM mAbs immunoprecipitated relatively little of the com- 
plex containing the excised intron-lariat RNA.  Each of the 
RNA species immunoprecipitated contains exon sequences 
whereas  the  intron-lariat  RNA  does  not,  but  instead  is 
bound to snRNPs in a stable postsplicing complex (Konarska 
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Anti-NM mAbs 
Property  B1C8  H1B2  B4AI 1 
Nuclear localization  speckles  speckles  speckles 
Immunoprecipitation of 
splicing complexes  +  +  + 
Splicing inhibition  +  -  + 
Recognition of defined 
SR proteins  +  (30 kD)  +  (55 kD) 
Major antigen 
probably SR related  180/160  kD*  ,~240 kD*  ,x,300 kD* 
* Sizes refer w the most prominent reactive species, all of which are preeipita- 
ble with high Mg  2+. The B1C8 antigen migrates as a doublet consisting of 180 
kD and '~ 160-kD proteins. The predominant H1B2 antigen is ,o240 kD. B4AI 1 
mAb reacts primarily with a ,,o300-kD antigen and weakly with a 80-kD doublet 
which is not Mg  2+ precipitable. 
Figure 9. Competition of nuclear staining by SR proteins. CaSki 
cells were stained with mAbs pre-incubated with (right column, B, 
D, F, H, and J) or without (left  column, A, C, E, G, and I) purified 
SR proteins (see Materials and Methods). mAbs used are: H1B2 
(A and B); B1C8 (C and D); B4All (E and F); SC35 (G and H), 
and YI2 (I and J). Each panel shows several cells representative 
of the entire field. Each pair of images in the left and right columns 
were recorded using identical exposures. 
and Sharp,  1987). Consistent with the NM antigens having 
an important role in splicing, both steps of pre-mRNA splic- 
ing were completely inhibited when either B1C8 or B4All 
was added to a reaction. The addition of H1B2 mAb had no 
effect on  splicing  although the antigen was  bound to  the 
spliceosome. None of the antigens recognized by the three 
anti-NM mAbs correspond to components of the abundant 
U1,  U2,  U4/6,  or  U5  snRNPs.  Immunoblotting and  bio- 
chemical assays suggest that the B1C8 and H1B2  antigens 
may be related to different members of the SR family of pro- 
tein splicing factors. 
It  is  intriguing  that  the  three  anti-NM  rnAbs,  which 
specifically react in a speckled pattern with the nuclear ma- 
trix, share the ability to preferentially bind to RNA contain- 
ing exon sequences.  In fact, the anti-NM mAbs preferen- 
tiaUy immunoprecipitated exon-contalning RNAs from three 
distinct splicing substrates. The preferential immunoprecipi- 
tation of  exon-contalning RNA sequences by the B1C8, H1B2 
and B4A11 mAbs was specific. Other mAbs against nuclear 
antigens did not show this pattern of immunoprecipitation. 
As expected, antibodies against snRNP Sm antigens prefer- 
entially immunoprecipitated complexes containing snRNPs. 
In contrast to the recent results of Zeng et al. (1994), several 
different antibodies  to the  nuclear matrix protein NuMA 
(Nuclear  mitotic  apparatus  protein)  (Yang  et  al.,  1992; 
Compton et al., 1991), immunoprecipitated neither splicing 
complexes, nor RNA. These anti-NuMA antibodies do not 
show a  speckled pattern but instead give essentially a uni- 
form nuclear staining. 
The B1C8, H1B2,  and B4All  anti-NM mAbs recognize 
different antigens. These antigens have separate and distinct 
behaviors at mitosis and also have distinct properties in as- 
says of nuclear extracts. Immunoblotting of proteins from 
HeLa nuclear extract with the anti-NM mAbs revealed dis- 
tinct patterns of reactivity. All three anti-NM mAbs reacted 
predominantly with  different high  molecular weight pro- 
teins. These proteins may be related to members of the SR 
family of proteins, which are concentrated in speckles and 
are associated with splicing complexes. Similar to SR pro- 
teins, all of these high molecular weight proteins were selec- 
tively precipitated from nuclear extract by high Mg  2+ con- 
centrations.  Significantly,  the  B1C8 and  HIB2  anti-NM 
mAbs also reacted at much lower efficiency  with specific SR 
proteins in purified preparations. Depleting nuclear extracts 
of SR proteins prevented immunoprecipitation of  pre-mRNA 
by all three mAbs. Addition of purified SR proteins restored 
immunoprecipitation of pre-mRNA by the B1C8 and H1B2 
mAbs but not the B4A11 mAb. Unlike the BIC8 and HIB2 
mAbs, the B4A11 mAb did not react with any of the purified 
SR proteins. Furthermore, purified SR proteins did not sig- 
nificantly compete inhibition of splicing or immunofluores- 
cent staining of nuclei by the B4A11 mAb. The data suggest 
that the BIC8 and HIB2 mAbs immunoprecipitate splicing 
complexes by binding to one or more proteins which may be 
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sequences. In contrast, the B4All mAb recognizes an anti- 
gen with similar properties, but which may not contain an 
epitope common to the purified SR proteins. 
The  apparent  relationship between the  high  molecular 
weight proteins  detected by the  anti-NM  mAbs  and  SR 
proteins is intriguing and raises the possibility that these pro- 
teins belong to an extended class of Mg  2+ precipitable pro- 
teins which are related to the SR family. The experiments 
with the SC35 mAb strengthen the apparent link between SR 
proteins and the cognate proteins of the anti-NM mAbs. The 
SC35 mAb recognizes several members of the SR protein 
family (Fu and Maniatis, 1990; Fu et al., 1992).  This anti- 
body gives essentially the same speckled immunofluores- 
cence as the anti-NM mAbs and also an identical pattern of 
immunoprecipitation from splicing reactions. We note how- 
ever that since none of the mAbs are uniquely specific for 
individual proteins in nuclear extracts, it is not possible to 
distinguish which of the cognate antigens are responsible for 
the different activities observed. This may not be surprising 
as a notable feature of SR proteins is their overlapping func- 
tional activities in certain in vitro assays. For example, any 
one of the purified SR proteins can restore activity to a splic- 
ing deficient S100 cytoplasmic extract which is depleted of 
SR proteins (Zahler et al., 1992, 1993). Likewise, it is possi- 
ble that the high molecular weight B1C8 and H1B2 antigens 
correspond to large SR proteins which overlap in function 
with the purified SR proteins. 
The nuclear matrix consists of a complex lattice of inter- 
connecting filaments composed of protein and RNA  (re- 
viewed in Nickerson and Penman, 1992).  This substructure 
retains splicesome components including snRNPs and also 
non-snRNP  splicing  factors  (Vogelstein  and Hunt,  1982; 
Spector et al.,  1983;  Verheijen et al.,  1986;  Smith et al., 
1986, 1989).  Evidence that splicing occurs in association 
with the nuclear matrix was first provided by Zeiflin and co- 
workers, who reported that a/~-globin pre-mRNA retained 
on the nuclear matrix was rapidly processed following the 
addition of a soluble nuclear fraction (Zeitlin et al., 1987). 
More recently, fluorescent in situ hybridization using gene- 
specific exon and intron probes have detected RNA tracks in 
association with the nuclear matrix (Lawrence et al., 1989; 
Huang and Spector, 1991; Xing et al., 1993).  Significantly, 
both  the  quantitative  and  qualitative  appearance  of  in- 
dividual RNA tracks was preserved during a matrix prepara- 
tion consisting of removal of  95 % of chromatin and also bulk 
protein  and  phospholipid  material  (Xing  and  Lawrence, 
1991). Based on these observations, it has been proposed that 
the nuclear matrix may provide a  solid support on which 
both RNA splicing and transport takes place. This view of 
pre-mRNA processing on the nuclear matrix may also ex- 
plain the observation of nonrandom paths followed by tran- 
scripts in Drosophila polytene nuclei (Zachar et al., 1993). 
The present study supports a role for the nuclear matrix 
in RNA processing. In this model, nuclear matrix proteins 
which include SR proteins and SR-associated factors, func- 
tion in the recognition and sequestration of exon sequences 
during the processing of pre-mRNA.  The SR protein sub- 
components of the matrix may be responsible for the exon 
recognition.  This  is  consistent  with  recent  experiments 
showing that the activities of SR proteins on splicing in vitro 
are dependent upon purine-rich sequences in exons (Lavig- 
ueur et al., 1993; Sun et al., 1993). Also sequestered in the 
matrix  are  the  snRNPs  and  non-snRNP  splicing  factors 
which  promote the  formation of spliceosomes.  Many of 
these  splicing factors,  such as:  SC35  (Fu and  Maniatis, 
1991),  ASF/SF2  (Ge et al.,  1991; Krainer et al.,  1991), 
U2AF (Zamore et al,,  1992;  Zhang et al.,  1992),  and the 
U1 snRNP 70-kD protein (Theissen et al., 1986), possess SR 
domains. The association of SR domains appears to be criti- 
cal for the activities of these proteins in splicing and could 
also be the point of their attachment to the matrix (Li and 
Bingham, 1991). This model extends to cases of alternative 
splicing, in which the selection and utilization of specific 
splice sites could be determined by their proximity to bind- 
ing  to  the  matrix.  For  example,  several  of the  proteins 
responsible for regulation of the alternative splicing patterns 
in  sex  determination  in  Drosophila contain  SR  repeats 
(McKeown et al., 1987; Amrein et al., 1988; Goralski et al., 
1989).  These proteins bind to RNA in a sequence-specific 
manner and promote the utilization of nearby splice sites 
(Hedley and Maniatis,  1991; Inoue et al.,  1992;  Tian and 
Maniatis, 1993). Perhaps these proteins regulate alternative 
splicing patterns by association of the nearby splice site with 
other SR proteins,and splicing factors in the nuclear matrix. 
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